1. Home
  2. NNY vs MNOV Comparison

NNY vs MNOV Comparison

Compare NNY & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen New York Municipal Value Fund

NNY

Nuveen New York Municipal Value Fund

SELL

Current Price

$7.97

Market Cap

154.3M

Sector

Finance

ML Signal

SELL

Logo Medicinova Inc

MNOV

Medicinova Inc

HOLD

Current Price

$1.51

Market Cap

137.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NNY
MNOV
Founded
1987
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
154.3M
137.8M
IPO Year
N/A
2004

Fundamental Metrics

Financial Performance
Metric
NNY
MNOV
Price
$7.97
$1.51
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
★ $8.25
AVG Volume (30 Days)
72.1K
★ 801.4K
Earning Date
01-01-0001
11-11-2026
Dividend Yield
★ 4.04%
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $2,360,807.00
Revenue This Year
N/A
$78.20
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 194.15
52 Week Low
$7.55
$1.17
52 Week High
$8.94
$3.90

Technical Indicators

Market Signals
Indicator
NNY
MNOV
Relative Strength Index (RSI) 52.81 38.52
Support Level $7.55 $1.29
Resistance Level $8.75 $1.86
Average True Range (ATR) 0.15 0.17
MACD 0.04 -0.10
Stochastic Oscillator 71.93 3.32

Price Performance

Historical Comparison
NNY
MNOV

About NNY Nuveen New York Municipal Value Fund

Nuveen New York Municipal Value Fund Inc. is a diversified closed-end management investment company. The Fund seeks to provide current income exempt from regular federal, New York State, and New York City income taxes, and from the federal alternative minimum tax for individuals, while enhancing portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds considered underrated, undervalued, or from undervalued municipal market sectors. It may invest in municipal securities such as lease obligations and certificates of participation, which provide an undivided interest in pools of municipal leases or installment purchase agreements.

About MNOV Medicinova Inc

MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.

Share on Social Networks: